Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating nephropathy

A composition and drug technology, applied in the field of pharmaceutical compositions for the treatment of nephropathy, can solve the problems of insufficient prevention of diabetic nephropathy progression and high incidence of adverse events

Inactive Publication Date: 2020-07-17
SHENZHEN TRADITIONAL CHINESE MEDICINE HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But in fact, on the one hand, sufficient use of RAS blockers cannot sufficiently prevent the progression of diabetic nephropathy; high rate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating nephropathy
  • Pharmaceutical composition for treating nephropathy
  • Pharmaceutical composition for treating nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0025] As used herein:

[0026] "Prepared from" is synonymous with "comprising". As used herein, the terms "comprises," "including," "has," "containing," or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a composition, step, method, article, or device comprising listed elements is not necessarily limited to those elements, but may include other elements not explicitly listed or inherent to such composition, step, method, article, or device. elements.

[0027] The conjunction "consisting of" excludes any unspecified elements, steps or components. If used in a claim, this phrase will make the claim closed so that it does not contain material other than those described except for the customary impurities associated therewith. When the phrase "consisting of" appears in a clause of the subject of a claim rather than immediately following the subject matter, it only defines the elements described in that clause; other elements are not e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition for treating nephropathy, and relates to the technical field of medicines. The pharmaceutical composition for treating nephropathy comprises astragaloside and an angiotensin converting enzyme inhibitor. Research finds that the astragaloside and the angiotensin converting enzyme inhibitor have a synergistic effect in a process of treating type 2 diabetic nephropathy, and the synergistic effect is shown in the aspects of reducing 24-hour urinary albumin excretion rate, reducing the concentration of oxidative stress product H2O2 in serum, reducing weight, improving kidney pathological injury, improving renal tubule atrophy condition, reducing blood pressure and the like.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to a pharmaceutical composition for treating nephropathy. Background technique [0002] Diabetic nephropathy is one of the most common complications of diabetes and the main cause of end-stage renal disease. At present, the prevention and treatment of diabetic nephropathy is mainly to control various risk factors. Albuminuria is a characteristic manifestation of diabetic nephropathy, and controlling the secretion of urinary albumin is a key measure to delay the progression of the disease. Therefore, the use of renin-angiotensin system (RAS) blockers, such as angiotensin converting enzyme inhibitors (angiotensin converting enzyme inhibitors, ACEi), angiotensin II-1 receptor antagonists (angiotensin- II type1receptor blocker, ARB), has also become the cornerstone of the treatment of diabetic nephropathy. But in fact, on the one hand, sufficient use of RAS blockers cannot sufficie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/7048A61P3/10A61P13/12
CPCA61K31/7048A61K45/06A61P3/10A61P13/12A61K2300/00
Inventor 孙惠力詹鸿越韩鹏勋邵牧民翁文慈余学问
Owner SHENZHEN TRADITIONAL CHINESE MEDICINE HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products